Oramed Pharmaceuticals outlines its oral drug strategy as Nasdaq-listed biotech pursues long-term growth

Oramed Pharmaceuticals (ISIN US68403P1003) is a clinical-stage biotechnology company listed on Nasdaq that is developing oral formulations of drugs that today are mainly administered by injection. The company focuses on metabolic and liver-related diseases, aiming to turn complex biologic therapies into capsules that are easier for patients to take.

Biotech working on oral therapies

Oramed Pharmaceuticals concentrates on drug candidates that leverage oral delivery technologies to protect sensitive molecules as they pass through the digestive system. The goal is to enable these medicines to be absorbed effectively in the gut without losing their therapeutic effect.

The company’s research and development activities center on areas such as diabetes and liver disease, where chronic treatment needs are high and patient adherence can be challenging. By designing drugs that can be taken orally, the company seeks to improve convenience for patients who might otherwise rely on regular injections.

Strategy and pipeline focus

Oramed Pharmaceuticals pursues a pipeline strategy built around its proprietary oral delivery platforms and formulation know-how. Its scientists work on optimizing capsules and tablets that can carry active pharmaceutical ingredients through the stomach and release them in parts of the intestine where absorption is more favorable.

In its development approach, the company typically advances candidates through preclinical testing and early-stage clinical studies to evaluate safety, dosing, and biological activity. Over time, successful projects can move into larger trials designed to substantiate efficacy in defined patient populations.

Representative oral drug concept

As a representative example of its work, Oramed Pharmaceuticals focuses on oral drug concepts that apply protective coatings and delivery systems to active ingredients that normally degrade in the stomach. These orally administered candidates are designed to survive gastric acid and enzymatic breakdown, reaching parts of the small intestine where they can be absorbed into the bloodstream.

In the broader biopharmaceutical industry, such oral delivery approaches can be relevant for hormones, enzymes, and other biologic molecules. By exploring formulations that improve stability and absorption, companies like Oramed Pharmaceuticals aim to expand the range of therapies that can be delivered by mouth rather than by injection.

Stock and listing overview

Oramed Pharmaceuticals stock trades on Nasdaq in the United States, reflecting its status as a publicly listed biotechnology issuer. The shares give investors exposure to the company’s efforts to develop oral formulations of complex drugs for chronic conditions.

This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.